Epidermal growth factor receptor (EGFR) is a classical target in head and neck cancer, and we found that the anti-EGFR therapy signature was enriched in the plac1-positive group (p < 0.001) (Supplementary Figures S5A,B). The gene discussed is EGFR; the disease is head and neck cancer.